| Company Name | Bayer Taiwan Company Ltd. |
|---|---|
| Protocol Number | 22453 |
| Title of Study | REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immuno-oncology immune checkpoint inhibitor combination in first-line. |
| Primary Objective | To describe the treatment outcomes (overall survival) of systemic treatments received after firstline systemic therapy with AB (atezolizumab in combination with bevacizumab) or another approved 1L-IO combo. |
| Number of Sites | 5 |
| Period of Study | From：2023/11/10 to：2027/02/10 |
| Number of Patients | 10人 |
| IRB Approval Date | Taipei Veterans General Hospital 送審中 Linkou Chang-Gung Memorial Hospital 送審中 National Taiwan University Hospital 23-Jan-2024 China Medical University Hospital 送審中 Taichung Veterans General Hospital 送審中 |
| Publication Plan / Date | 2027/11/10 |
